Soaring antiretroviral prices, TRIPS and TRIPS flexibilities: a burning issue for antiretroviral treatment scale-up in developing countries

  title={Soaring antiretroviral prices, TRIPS and TRIPS flexibilities: a burning issue for antiretroviral treatment scale-up in developing countries},
  author={Fabienne Orsi and Cristina d’Almeida},
  journal={Current Opinion in HIV and AIDS},
Purpose of reviewThe achievement of significant reductions in the price of antiretroviral drugs constitutes one of the main economic pillars of antiretroviral treatment scale-up in developing countries. Today this economic pillar is threatened. Recent findingsThe prohibitive prices of newer first-line and second-line regimens have created a watershed in relation to the prices of earlier first-line treatments. These price increases are closely related to the World Trade Organization's Agreement… 
Modeling HIV/AIDS Drug Price Determinants in Brazil: Is Generic Competition a Myth?
The results show that generic suppliers are more likely to respond to factors influencing demand size and market competition, while originator suppliers tend to set prices strategically to offset compulsory licensing threats and generic competition.
Low-cost generic drugs under the President's Emergency Plan for AIDS Relief drove down treatment cost; more are needed.
PEPFAR's evolving use of generic antiretroviral drugs to treat HIV in the developing world is outlined, ongoing initiatives to increase access are highlighted, and the need for mechanisms that will speed up the approval of new generic drugs is pointed to.
Treatment 2.0: catalyzing the next phase of treatment, care and support
An update on the WHO/UNAIDS Treatment 2.0 strategy articulates how innovation and greater efficiency can make HIV care and treatment more accessible and affordable, and guide treatment and prevention scale-up.
The politics behind the implementation of the WTO Paragraph 6 Decision in Canada to increase global drug access
The Canadian Government designed CAMR as a last resort measure and increased input from the developing country beneficiaries and shifting to institutions where the right to health gets prioritized may lead to policies that better achieves affordable drug access.
The Politics of Canada's Access to Medicines Regime: The Dogs that Didn't Bark
Decisions to reform pharmaceutical policy often involve trade-offs between competing social and commercial goals. Canada's Access to Medicines Regime (CAMR), a reform that permits compulsory
Ethical use of antiretroviral resources for HIV prevention in resource poor settings.
  • S. Rennie
  • Medicine
    Developing world bioethics
  • 2013
It is argued that selective, evidence-based allocation of ARVs for prevention in certain cases could be ethically justified even when there is insufficient anti-retroviral access for all those needing it for treatment.
Barriers to HIV/AIDS Treatment in Nigeria
Key issues or barriers militating against the smooth delivery of HIV/AIDS treatment services are identified and strategies for removing them are recommended in order to achieve the much desired universal access to HIV treatment.
The effects of setarud on the immunological status of HIV-positive patients: Efficacy of a novel multi-herbal drug
IMOD (as a herbal drug) has been successfully added to the HAART regimen to improve the immunological status of HIV-positive patients.
Post-coloniality and the movements and readings of scientific and legal practices : the history of HIV/AIDS in Africa, patents, and the multilateral governance of generic drugs
This thesis examines the history, political economy, and global response to HIV/AIDS in Africa. It is particularly interested in how Africa’s colonial past and postcolonial struggles with European
Maximizing the Delivery Performance of Point-of-Care CD4+ T-Cell Counting Tests in Resource-Limited Settings - A Policy Brief
Global Policy Research Institute 1341 Northwestern Avenue West Lafayette, IN 47906 Phone: (765) 496-6788 Fax: (765) 463-1837 Maximizing the Delivery Performance of


TRIPS post-2005 and access to new antiretroviral treatments in southern countries: issues and challenges
The end of the transitional period which effectively will prohibit the free manufacture of newer and innovative antiretroviral generations to mark a key episode in the history of the fight against AIDS in developing countries is marked.
Sustaining access to antiretroviral therapy in the less-developed world: lessons from Brazil and Thailand
Three factors were critical to this success: legislation for free access to treatment; public sector capacity to manufacture medicines; and strong civil society action to support government initiatives to improve access to antiretroviral therapy.
Drug resistance, patent resistance: Indian pharmaceuticals and the impact of a new patent regime
The effects of this new legal regime, the global political economy and emerging resistance to HIV/AIDS medications are analyzed, and efforts to mitigate the negative public health effects of the new patent laws are evaluated.
Addressing legal and political barriers to global pharmaceutical access: Options for remedying the impact of the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) and the imposition of TRIPS-plus standards
It is argued that several policy and research routes should be taken to mitigate the restrictive impact of TRIps and TRIPS-plus rules, including greater use of TRIPS flexibilities, advancement of human rights, and an ethical framework for essential medicines distribution.
The political economy of HIV/AIDS in developing countries : TRIPS, public health systems and free access
This book discusses the evolution of Prices and Quantities for ARV Drugs in African Countries: From Emerging to Strategic Markets, and the Public Health Approach to Antitretroviral Treatment in Cameroon.
An Economic Justification for Open Access to Essential Medicine Patents in Developing Countries
Open licenses that permit any qualified firm to supply the market on the same terms, such as may be available under licenses of right or essential facility legal standards, can be used to mitigate the negative effects of government-granted patents, thereby increasing overall social welfare.
Comment: Compulsory Licensing of Patented Pharmaceutical Inventions: Evaluating the Options
  • J. Reichman
  • Political Science
    The Journal of law, medicine & ethics : a journal of the American Society of Law, Medicine & Ethics
  • 2009
In this Comment, the author traces the relevant legislative history pertaining to compulsory licensing of patented pharmaceuticals from the TRIPS Agreement of 1994 to the 2003 waiver to, and later
Canada's implementation of the Paragraph 6 Decision: is it sustainable public policy?
Whether the CAMR can feasibly achieve its humanitarian objectives given the political interests embedded in the crafting of the legislation is investigated and a political economy framework is used to analyze the effect of varied institutions, political processes, and economic interests on public policy outcomes.